related_default

These related items will show up on every page (unless there are 8 other higher weighted matches in which case they will fall off)

Autism Trial with RG7314

This multi-center, randomized, double-blind, parallel group, placebo-controlled, proof of concept study will investigate the efficacy and safety of RG7314, a vasopressin 1a (V1a) receptor antagonist, in adult patients with autism spectrum disorders.

Summary

  • Study director: Robert Hendren, DO
  • Sponsor: Hoffman-La Roche
  • Recruiting?: Yes
  • Official study title: A Multi-center, Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)
  • ClinicalTrials.gov identifier: NCT01793441
  • Conditions studied: Autistic disorder

Autism Translation to Treatments Project

The AT3 Study is a novel prospective study which will carefully monitor young children who were recently diagnosed with autism and who are undergoing detailed biomedical evaluation and treatment with their regular physician at one of five study sites in the United States.

Summary

  • Study director: Robert Hendren, DO
  • Sponsor: Private Foundation: Jane Johnson Foundation
  • Recruiting?: Yes
  • Official study title: Autism Translation to Treatments (AT3) Project
  • Conditions studied: Autistic disorder

Autism Trial with Lurasidone

The purpose of this trial is to evaluate the efficacy and safety of two fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent subjects with irritability associated with autistic disorder who reside in the community setting.

Summary

  • Study director: Robert Hendren, DO
  • Sponsor: Sunovion
  • Recruiting?: No
  • Official study title: A 6-Week Randomized, Parallel, Double-Blind, Placebo Controlled, Fixed-Dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects with Irritability Associated with Autistic Disorder
  • ClinicalTrials.gov identifier: NCT01911442
  • Conditions studied: Autistic disorder

ASD Biomarker Study

This research study is aimed at better understanding the biological mechanisms underlying autism spectrum disorders. A first step towards this process would be development of an easily and reliably measurable biomarker, which requires an understanding of the common elements underlying ASD biology. In the proposed research, we aim to make rapid progress toward identifying a blood biomarker for autism spectrum disorders.

Summary

  • Study director: Elliott Sherr, MD PhD
  • Sponsor: NIH and private foundations and grants
  • Recruiting?: Yes
  • Official study title: Biomarker Discovery in Autism Spectrum Disorder (ASD)
  • Conditions studied: Autism spectrum disorders that have been clinically diagnosed

Multi-disciplinary Assessment Center (MDAC) at San Francisco General Hospital (SFGH)

The UCSF Multi-Disciplinary Assessment Center (MDAC) at San Francisco General Hospital provides family-centered assessment services, diagnosis, service linkage, short-term intervention and case management to children and families needing neurological, psychological and medical assessment for suspected or actual developmental delay. MDAC is supported by First5 San Francisco.

The UCSF Multi-Disciplinary Assessment Center (MDAC) at San Francisco General Hospital provides family-centered assessment services, diagnosis, service linkage, short-term intervention and case management to children and families needing neurological, psychological and medical assessment for suspected or actual developmental delay. MDAC is supported by First5 San Francisco.

SNAP Contact Form

The UCSF Pediatric Brain Center’s Sensory Neurodevelopment and Autism Program is committed to conducting new and relevant research. We frequently begin new studies that you or your child might be eligible for. This SNAP Contact Form allows us to keep you informed of new studies through email, phone and periodic newsletters.

The UCSF Pediatric Brain Center’s Sensory Neurodevelopment and Autism Program is committed to conducting new and relevant research. We frequently begin new studies that you or your child might be eligible for. This SNAP Contact Form allows us to keep you informed of new studies through email, phone and periodic newsletters. You may also contact Annie Brandes-Aitken at Anne.Brandes-Aitken@ucsf.edu for more information.

Autism Trial with Vitamin D

The study is a 12-week, open-label trial examining the tolerability of Vitamin D replacement in children with autism spectrum disorders. The study will evaluate whether Vitamin D replacement at high doses will show improvement in the core symptoms of autism, including sociability, eye contact, anger outbursts, stimming behavior, and sleep.

Summary

  • Study director: Robert Hendren, DO
  • Sponsor: Ddrops
  • Recruiting?: No
  • Official study title: Open Label Clinical trial of Vitamin D3 Dosage Tolerability and Effect on Behavioral Measures in Children with Autism
  • ClinicalTrials.gov identifier: Pending
  • Conditions studied: Autistic disorder
  • Intervention: Vitamin D3 (cholecalciferol)
  • Phase: Phase II

Adult Outcomes in Autism

In the past 15 years, estimates of autism prevalence have increased from 1:800 (DSM-IV, APA, 1994) to as high as 1:110 presently (2008, CDC). If as data suggest, most adults have limited prognoses, studying predictors of outcomes among those currently just reaching adulthood can provide an understanding of how to provide positive and cost-effective treatment.

Summary

  • Study director: Bryna Siegel, PhD
  • Sponsor: UCSF
  • Recruiting?: Yes
  • Official study title: Early Childhood Predictors of Adult Outcomes in Autism
  • Conditions studied: Adults who were diagnosed with an autism spectrum disorder before the age of 4 at the UCSF Autism Clinic

JumpStart Learning to Learn

The purpose of the study is to evaluate child and parent outcomes after participation in the treatment program JumpStart Learning-to-Learn (JSLTL). JSLTL is a new approach to early intervention for autism, best characterized as a "first intervention" consisting of an intensive, full-time week of parent and child trainings.

Summary

  • Study director: Bryna Siegel, PhD
  • Sponsor: Flora Foundation
  • Recruiting?: Yes
  • Official study title: Outcomes of JumpStart Learning to Learn
  • Conditions studied: Families with children recently diagnosed with autism who have participated in an intensive early intervention parent training program (JumpStart Learning to Learn)
  • Intervention: JumpStart Learning-to-Learn (JSLTL)
Syndicate content